MedTrace Logo

Efficacy of PRUcalopride in Critically Ill Patients With Paralytic ILeus

NCT04190173 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2020-02-06

No results posted yet for this study

Summary

Paralytic ileus is a common intestinal dysfunction in critically ill patients. There are still no established the effective medications except correcting the primary causes and prokinetics trial which limited in efficacy and potential adverse events.

Conditions

  • Paralytic Ileus
  • Critically Ill

Interventions

DRUG

Prucalopride

1-2 mg once daily enteral feeding for 5 consecutive days

DRUG

Placebo

1/2-1 tablet once daily enteral feeding for 5 consecutive days

Sponsors & Collaborators

  • Prince of Songkla University

    lead OTHER

Principal Investigators

  • Sawangpong Jandee, Dr. · Faculty of Medicine, Prince of Songkla University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2020-01-30
Completion
2020-02-15

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04190173 on ClinicalTrials.gov